Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05012618 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT05012618: Clinical Trial Phase 1 study, sponsored by Chugai Pharmaceutical.
NCT05012618 is a Phase 1 study that was terminated before completion, run by Chugai Pharmaceutical. The registered enrollment target is 128 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05012618, a Phase 1 study, was terminated before completion, sponsored by Chugai Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metastatic solid tumors.
Primary Outcome
Incidence and nature of dose-limiting toxicities (DLTs)
Interventions
- DRUG Cetuximab
- DRUG LUNA18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 1 |
Why NCT05012618 stopped before completion
NCT05012618 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher).
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT05012618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05012618 about?
NCT05012618 is a clinical study titled "A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).". This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metasta...
What is the current status of trial NCT05012618?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2021-10-08. Estimated completion is 2025-11-13.
What interventions are being tested in trial NCT05012618?
The interventions under investigation include: Cetuximab (DRUG), LUNA18 (DRUG).
Who is sponsoring clinical trial NCT05012618?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05012618's enrollment target sits among peer trials
128 452nd of 2000 higher than 1,542 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI